Dergiler / Marmara Medical Journal / 2015 / Special Issue 1: Oncology

What to expect from HER-2 directed therapies in advanced gastric cancer?

Sayfa
11–15
Yayın Tarihi
2015-09-30
DOI
—
🏛️Bu makalenin bibliyografik verileri ve tam metin bağlantısı DergiPark üzerinden sağlanmıştır.
DergiPark Kaydı ↗
✨

Yapay Zeka Hızlı Bakış & Çıkarımlar

AI Insight
⚡ TL;DR(1 Cümlede Hızlı Çıkarım)

Inthis review, I will briefly summarize the clinical studies ofanti-HER-2 therapies performed in HER-2 positive gastriccarcinoma.Keywords: Gastric cancer, HER-2/neu, Targeted therapy

📌 3 Maddede Bu Makale

🎯
Amaç & Hipotez:Gastric cancer is the second most common cause of cancerrelated death worldwide.
📊
Temel Bulgular & Veri:Over 20% of the advanced gastriccancer are considered to be HER-2 positive.
💡
Sonuç & Katkı:Inthis review, I will briefly summarize the clinical studies ofanti-HER-2 therapies performed in HER-2 positive gastriccarcinoma.Keywords: Gastric cancer, HER-2/neu, Targeted therapy
🔬Tür:Literatür & Derleme Çalışması
📍Kapsam:Genişletilmiş Akademik Örneklem
⚙️Değişkenler:Gastric cancer · HER-2/neu · Targeted therapy

Abstract

Gastric cancer is the second most common cause of cancerrelated death worldwide. Over 20% of the advanced gastriccancer are considered to be HER-2 positive. Studiesinvestigating the prognosis of HER-2 positive advancedgastric cancer revealed conflicting results. Trastuzumab, amonoclonal antibody against HER-2, has shown a significantclinical activity in HER-2 positive gastric cancer patients. Inthis review, I will briefly summarize the clinical studies ofanti-HER-2 therapies performed in HER-2 positive gastriccarcinoma.Keywords: Gastric cancer, HER-2/neu, Targeted therapy

🔖

Bu Makaleye Atıf Yap

DANE, F. (2015). What to expect from HER-2 directed therapies in advanced gastric cancer?. Marmara Medical Journal, Special Issue 1: Oncology, 11–15. https://ajindex.com/articles/688367

📄 Tam Metin PDF Okuyucu

📄

PDF görüntüleyici hazırlanıyor...

Kaynakça (10)

  1. Garcia M, Jemal A, Ward EM, et al. Global cancer facts and figures 2007. Atlanta, GA: American Cancer Society, 2007
  2. Kamangar F, Dores GM, Anderson WF. Patterns of cancer incidence, mortality, and prevalence across fi ve continents: defining priorities to reduce cancer disparities in different geographic regions of the world. J Clin Oncol 2006; 24: 2137–50. doi: 10.1200/ JCO.2005.05.2308 3. Cunningham D, Starling N, Rao S, et al. Capecitabine and oxaliplatin for advanced esophagogastric cancer. N Engl J Med 2008; 358:36. doi: 10.1056/NEJMoa073149
  3. Ajani JA, Moiseyenko VM, Tjulandin S, et al. Clinical benefit with docetaxel plus fluorouracil and cisplatin compared with cisplatin and fluorouracil in a phase III trial of advanced gastric or gastroesophageal cancer adenocarcinoma: the V-325 Study Group. J Clin Oncol 2007; 25:3205. doi: 10.1200/JCO.2006.10.4968 5. Schechter AL, Hung MC, Vaidyanathan L, et al. The neu gene: an erbB-homologous gene distinct from and unlinked to the gene encoding the EGF receptor. Science 1985; 229(4717):976-8
  4. Yamamoto T, Ikawa S, Akiyama T, et al. Similarity of protein encoded by the human c-erb-B-2 gene to epidermal growth factor receptor. Nature 1986;319(6050):230-4
  5. Park YS, Hwang HS, Park HJ, et al. Comprehensive analysis of HER2 expression and gene amplification in gastric cancers using immunohistochemistry and in situ hybridization: which scoring system should we use? Hum Pathol 2012; 43:413. doi: 10.1016/j. humpath.2011.05.019
  6. Barros-Silva JD, Leitão D, Afonso L, et al. Association of ERBB2 gene status with histopathological parameters and disease-specific survival in gastric carcinoma patients. Br J Cancer 2009; 100:487. doi: 10.1038/ sj.bjc.6604885
  7. Baykara M, Benekli M, Ekinci O, Irkkan C,DemirciU, Karaca H, Unal O.U,Dane F, Akinci B, Turkoz F.P. Clinical significance of HER2 overexpression in gastric and gastro-esophageal junction cancers: Is there any discordance between IHC and FISH. ESMO 2012, abst:2778
  8. Hofmann M, Stoss O, Shi D, et al. Assessment of a HER2 scoring system for gastric cancer: results from a validation study. Histopathology 2008;52:797-805. doi:10.1111/j.1365-2559.2008.03028.x
  9. Bang Y, Chung H, Xu J, et al. Pathological features of advanced gastric cancer (GC): Relationship to human epidermal growth factor receptor 2 (HER2) positivity in the global screening programme of the ToGA trial (abstract). J Clin Oncol 2009; 27:215s
  10. Rüschoff J, Dietel M, Baretton G, et al.